
ESOCAP HOLDS A MULTIDISCIPLINARY SCIENTIFIC ADVISORY BOARD MEETING WITH THIRTEEN INTERNATIONAL EXPERTS



Basel, Switzerland, June 27, 2019

EsoCap AG organized a multidisciplinary scientific advisory board meeting in Zurich with thirteen international experts on June 27, 2019.

As an introduction, Prof. Werner Weitschies, Center for Drug Absorption and Transport at the University of Greifswald, gave a presentation on the Esophageal Wafer Study conducted in healthy volunteers by the University of Greifswald. The excellent results regarding acceptability and functionality were shared with the experts.

EsoCap AG presented the clinical development approach for its unique drug delivery technology in the first indication, EOE (eosinophilic esophagitis). The experts discussed the role of EsoCap's technology for the topical treatment of EoE and explored the broader application of EsoCap's drug delivery platform in reflux disease and Barrett's esophagus.

The participants in this scientific advisory board meeting included thirteen distinguished experts from Germany, the Netherlands, Spain, Sweden, the UK, Switzerland and the USA, all internationally recognized for their expertise in EoE. The experts' multidisciplinary backgrounds in gastroenterology, immunology, pharmacology, pathology, surgery and ENT (ear nose and throat) allowed a particularly fruitful exchange.

"I am highly impressed by the demonstration of the EsoCap technology's functionality", said Prof. Alfredo Lucendo, Hospital General de

Tomelloso, Spain. "The development in EoE is just the beginning. The EsoCap technology has tremendous potential to offer new treatment options for diseases of the esophagus."

"Thanks to the experts' insightful contributions, we are looking forward to moving rapidly into clinical testing of our unique application technology," said Isabelle Racamier, EsoCap AG CEO.

About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique topical drug delivery platform.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve, due to ultra-short transit times, with less than two seconds from mouth to stomach.

EsoCap owns a unique drug delivery platform, allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocap-biotech.com.



EsoCap

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com